ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0006675 | A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. | Elemental calcium|Calcium (NOS)|Calcio|CALCIUM|Factor IV, Coagulation|CA|Coagulation Factor IV|calciums|calcium|Kalzium|Calcium 40|Calcium-containing product|Factor IV|Ca|Calcium-40|Ca++ element|Product containing calcium (medicinal product)|Blood Coagulation Factor IV|factor iv|Coagulation factor IV|Calcium coagulation factor|Calcium|Calcium (substance)|Calcium, elemental|Ca - Calcium|Calcium, coagulation factor|Calcium, NOS|Ca element | calcium |
C0205065 | Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus. | Ovaro-|ovarian|Ovarian | Ovarian |
C0037949 | The spinal or vertebral column. | Spinal Column|Structure of vertebral column (body structure)|Spinal Columns|backbones|Structure of vertebral column|Spinal column, NOS|Column, Spinal|Spine|VERTEBRAL COLUMN|Column, Vertebral|Vertebral Columns|spinal column|Vertebral column|spines|Spinal column|Columns, Vertebral|Columns, Spinal|SPINAL COLUMN|vertebral column|spine|Spine, NOS|Vertebral column, NOS|backbone|Columna vertebralis|Vertebral Column|Backbone | Vertebral column |
C0221629 | A lack of strength of the proximal muscles. [HPO:probinson] | Weakness in muscles of upper arms and upper legs|Muscle weakness, proximal|PROXIMAL MUSCLE WEAKNESS|Proximal limb muscle weakness|muscles proximal weakness|Proximal muscle weakness|Proximal limb weakness|Proximal muscle weakness (finding)|proximal muscle weakness | Proximal muscle weakness |
C0185283 | Removal of tissue from the muscle, for microscopic examination. | Biopsy of Muscle|Biopsy of muscle|Muscle Biopsy|of muscle biopsy|biopsy muscle|biopsies muscle|biopsy of muscle|Biopsy of muscle, NOS|Biopsy of muscle (procedure)|muscle biopsy | Muscle biopsy |
C0015278 | An enzyme that catalyzes the hydrolysis of terminal 1,4-linked alpha-D-glucose residues successively from non-reducing ends of polysaccharide chains with the release of beta-glucose. It is also able to hydrolyze 1,6-alpha-glucosidic bonds when the next bond in sequence is 1,4. | glucan 1,4 alpha glucosidase|1, 4-Alpha-Glucosidase|gamma Amylase|amyloglucosidase|lysosomal alpha glucosidase|Exo-1,4-alpha-glucosidase|Acid maltase|1,4-alpha-Glucosidase, Exo|Exo 1,4 alpha Glucosidase|alpha-Glucosidase, lysosomal|Glucoamylase|1,4-alpha-D-Glucan glucohydrolase|gamma amylase|acid maltase|Gamma-amylase|Glucan 1,4-alpha-Glucosidase|gamma-Amylase|Exo-1,4-alpha-Glucosidase|Glucan 1,4 alpha Glucosidase|exo 1,4 alpha glucosidase|1,4-alpha-Glucosidase, Glucan|Lysosomal alpha-glucosidase|Alpha-1,4-glucosidase|Glucan 1,4-alpha-glucosidase (substance)|Glucan 1,4-alpha-glucosidase|Amyloglucosidase|glucoamylase | Glucan 1,4-alpha-Glucosidase |
C0206157 | A group of inherited congenital myopathic conditions characterized clinically by weakness, hypotonia, and prominent hypoplasia of proximal muscles including the face. Muscle biopsy reveals large numbers of rod-shaped structures beneath the muscle fiber plasma membrane. This disorder is genetically heterogeneous and may occasionally present in adults. (Adams et al., Principles of Neurology, 6th ed, p1453) | Nemaline myopathy (disorder)|Rod Myopathy|Rod myopathy|Rod-Body Myopathy|Nemaline Myopathy|Rod Body Myopathy|Rod-body myopathy|Myopathies, Rod|Rod Myopathies|Nemaline Myopathies|Myopathy, Rod Body|Nemaline body disease|Myopathy, Rod|Myopathy, Rod-Body|Myopathy, Nemaline|Nemaline Rod Disease|nemaline myopathy|rod myopathy|Nemaline myopathy|Rod Body Disease|Rod-Body Myopathies|Nemaline Body Disease|Myopathies, Rod-Body | Myopathies, Nemaline |
C0337527 | A male sibling. | brothers|Brother, NOS|brother|Brothers|Brother|Brother (person) | Brothers |
C0012472 | The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. | PGE2 preparation|E2, Prostaglandin|Dinoprostone Prostaglandin E2|alpha, Prostaglandin E2|Prostaglandin PGE2|Prostaglandin E2 preparation|(15S)-prostaglandin E2|dinoprostone|Dinoprostona|DINOPROSTONE|e2 prostaglandin|PGE2|Product containing dinoprostone (medicinal product)|Dinoprostonum|(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate|(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid|Prostaglandin E2 alpha|PGE2alpha|Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-|(5Z,11α,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid|Prostaglandin E2alpha|Dinoprostone (substance)|E2alpha, Prostaglandin|Dinoprostone|pge2 alpha|Dinoprostone-containing product|PGE2 alpha|alpha, PGE2|(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid|PGE2 - prostaglandin E2|Dinoproston|(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate|E2 alpha, Prostaglandin|pge2|Prostaglandin E2|prostaglandin e2|Dinoprostone preparation | dinoprostone |
C1281026 | null | Entire dentate gyrus|Entire dentate gyrus (body structure) | Entire dentate gyrus |
C0016377 | An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE. | Fluriproben|Flurbiprofen|flubiprofen|Flurbiprofen (substance)|Flurbiprofenum|Flurbiprofen-containing product|flurbiprofen|2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic Acid|2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid|2-(2-fluorobiphenyl-4-yl)propanoic acid|2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid|FLURBIPROFEN|Product containing flurbiprofen (medicinal product)|(±)-2-fluoro-α-methyl-4-biphenylacetic acid|2-fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid|(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-|3-fluoro-4-phenylhydratropic acid|Flurbiprofene|Flubiprofen|Flurbiprofeno | flurbiprofen |
C0040845 | An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). | all trans Retinoic Acid|all-trans-retinoic acid|Acid, Retinoic|3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|Vitamin A acid, all-trans-|Product containing tretinoin (medicinal product)|trans Retinoic Acid|Trans Retinoic Acid|Vitamin A Acid|all-trans-beta-Retinoic acid|Acid, trans-Retinoic|vitamin a acid|all-trans-Vitamin A1 acid|All-trans Vitamin A Acid|2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-|beta-retinoic acid|TRA|all trans Retinoic acid|retinoic acid|Retinoic Acid|Acide retinoique|(All-E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|Tretinoin-containing product|Tretinoin (substance)|all-trans-Tretinoin|trans-Retinoic Acid|All-trans Retinoic Acid|Tretinoin|beta-Retinoic Acid|Retinoic acid|trans retinoic acid|(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid|tretinoin|all-trans retinoic acid|all-trans-Retinoic acid|TRETINOIN|Acid, Vitamin A|tretinoinum|Tretinoina|Tretinoinum|all-(E)-Retinoic acid|all-trans vitamin A acid|Vitamin A acid|Trétinone|trans vitamin A acid|all-trans-Retinoic Acid|all trans retinoic acid|all trans-Retinoic acid|vitamin A acid|ATRA|Trans Vitamin A Acid|beta-Retinoic acid|all-trans-Vitamin A acid|trans-Retinoic acid|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)|Acid, all-trans-Retinoic|Tretin M|Retionic acid|(All-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid | tretinoin |
C0007776 | The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulchi. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. | Cortex Cerebrus|Cortex cerebri|Cerebral cortex|Cortex cerebralis|cerebral cortex|Cerebrus, Cortex|Grey matter|Cortex of cerebral hemisphere|Pallium|Cerebral Cortices|Structure of cerebral cortex (body structure)|Cortical|Plates, Cortical|Cerebral Cortex|Cerebral gray matter|Cortical Plates|Cerebri, Cortex|pallium|Cortex|Cortex Cerebri|Structure of cerebral cortex|Cortex, Cerebral|CEREBRAL CORTEX|Cortices, Cerebral|Cortical Plate|Cortex of cerebrum|Plate, Cortical | Cerebral cortex |
C0042839 | Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products. | VITAMIN A|VITAMIN A PREPARATIONS|Retinol|viatmin a|Vitamin A preparation|Product containing retinol (medicinal product)|a vitamin|Retinol (substance)|retinols|RETINOL|retinol (vit A)|Vitamin A USP|Vitamin A|vit a|vitamin-a|retinol|vitamin A|Retinol-containing product | vitamin A |
C0013030 | One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. | Dopamine (substance)|4-(2-aminoethyl)catechol|3,4 Dihydroxyphenethylamine|DOPamine|4-(2-aminoethyl)pyrocatechol|DOPAMINE|2-(3,4-dihydroxyphenyl)ethylamine|Oxytyramine|3,4-Dihydroxyphenethylamine|4-(2-Aminoethyl)benzene-1,2-diol|4-(2-aminoethyl)-1,2-benzenediol|3-Hydroxytyramine|Dopamine|Hydroxytyramine|4-(2-Aminoethyl)-1,2-benzenediol|Dopamine preparation|Product containing dopamine (medicinal product)|1,2-Benzenediol, 4-(2-aminoethyl)-|Dopamine-containing product|dopamine|Dopamina|Dopaminum | dopamine |
C0175413 | A region in the substantia nigra located ventral and lateral to the PARS COMPACTA. | substantia nigra pars reticulata|Reticulata, Pars|Nigra Reticulata, Substantia|Reticularis, Pars|Reticulatas, Substantia Nigra|Pars Reticularis|Pars Reticulari|Pars reticularis substantiae nigrae|Substantia Nigra Reticulata|Reticulatas, Pars|pars reticulata|Substantia Nigra Pars Reticulata|Substantia Nigra Reticulatas|Pars Reticulatas|Substantia nigra pars reticulata|Reticulata, Substantia Nigra|Pars Reticulata|Substantia nigra, pars diffusa|Reticular part of substantia nigra|pars reticularis|Pars reticularis|Substantia Nigra, Pars Reticulata|Nucleus substantiae nigrae, Pars reticularis|Substantia nigra, reticular part|Nigra Reticulatas, Substantia|Pars reticulata|Reticulari, Pars | pars reticulata of substantia nigra |
C0392702 | dyskinesia due to extrapyramidal disorder; as a general rule, symptoms are absent during sleep, reduced with relaxation, and increased with stress. | Abnormal involuntary movement (disorder)|abnormal involuntary movements|abnormal involuntary movement|Abnormal involuntary movements|Abnormal involuntary movement | Abnormal involuntary movement |
C0023570 | The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. | L-3,4-dihydroxyphenylalanine|Levodopum|Levodopa-containing product|L 3,4-dihydroxyphenylalanine|(-)-3-(3,4-dihydroxyphenyl)-L-alanine|dopa l|3-hydroxy-L-tyrosine|L(-)-Dopa|l dopa|l dopa levodopa|(--)-2Amino-3-(3,4-dihydroxyphenyl)propanoic Acid|3-Hydroxy-L-tyrosine|L 3,4 Dihydroxyphenylalanine|Product containing levodopa (medicinal product)|(--)-3-(3,4-Dihydroxyphenyl)-L-alanine|levodopa|Dihydroxy-L-phenylalanine|L-beta-(3,4-Dihydroxyphenyl)alanine|(--)-2amino-3-)3,4-dihydroxyphenyl)propanoic acid|LEVODOPA|β-(3,4-dihydroxyphenyl)alanine|L-3-hydroxytyrosine|beta-(3,4-Dihydroxyphenyl)-L-alanine|beta-(3,4-dihydroxyphenyl)-L-alanine|(--)-3-(3,4-dihydroxyphenyl)-L-alanine|(-)-dopa|L-.beta.-(3,4-Dihydroxyphenyl)alanine|3-(3,4-Dihydroxyphenyl)-L-alanine|L-Dopa|Levodopa (substance)|β-(3,4-dihydroxyphenyl)-L-alanine|L-dopa|Levodopa|.beta.-(3,4-Dihydroxyphenyl)-L-alanine|L Dopa|l-dopa|3 Hydroxy L tyrosine|L-DOPA|3,4-Dihydroxy-L-phenylalanine|L-dopa preparation|(-)-3-(3,4-Dihydroxyphenyl)-L-alanine|L-3,4-Dihydroxyphenylalanine | levodopa |
C0013384 | Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES. | Abnormal Movement|Disorder of involuntary muscle movements|Dyskinesia|Dyscinesia|Abnormal Movements|Movements, Abnormal|Dyskenesic|DYSKINESIA|dyskinesia|Movement, Abnormal|Dyskinesia (finding)|Dyskinesis|Dyskinesias|SYNDROME DYSKINETIC | Dyskinetic syndrome |
C0035344 | A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed) | Retinopathy of prematurity NOS|Retinopathy of prematurity|Retinopathy of prematurity, unspecified|Retrolental Fibroplasias|Retrolental fibroplasia|prematurity of retinopathy|ROP - Retinopathy of prematurity|retinopathy prematurity|premature retinopathy|Fibroplasias, Retrolental|RLF - Retrolental fibroplasia|RETINOPATHY OF PREMATURITY|Fibroplasia, Retrolental|Retinopathy of Prematurity|ROP|prematurity retinopathy rop|RLF|RETROLENTAL FIBROPLASIA|Retrolental Fibroplasia|Terry's syndrome|retinopathy premature|Terry Syndrome|Retinopathy of prematurity (disorder)|rlf|fibroplasia retrolental|Prematurity Retinopathy|prematurity retinopathy|Prematurity Retinopathies|retrolental fibroplasia|retinopathy of prematurity | Retinopathy of Prematurity |
C0035567 | annual cereal grass Oryza sativa and its edible starchy grain, which is the staple food of roughly one-half of the world's population. | Rice|Rice (substance)|Rices|Rice, NOS|rice | Rice (Dietary) |
C0120285 | Protein analogs and derivatives of the Aequorea victoria green fluorescent protein that emit light (FLUORESCENCE) when excited with ULTRAVIOLET RAYS. They are used in REPORTER GENES in doing GENETIC TECHNIQUES. Numerous mutants have been made to emit other colors or be sensitive to pH. | Green fluorescent protein|GFP|Green-Fluorescent Proteins|gfp|Proteins, Green-Fluorescent|Proteins, Green Fluorescent|Fluorescent Proteins, Green|green fluorescent protein | Green Fluorescent Proteins |
C0014520 | The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis). | Epidermis structure|epidermis|Epidermis|Epidermal|Epidermis structure (body structure)|Entire portion of epidermis|EPIDERMAL TISSUE | Epidermis |
C0162741 | A plant genus of the family BRASSICACEAE that contains ARABIDOPSIS PROTEINS and MADS DOMAIN PROTEINS. The species A. thaliana is used for experiments in classical plant genetics as well as molecular genetic studies in plant physiology, biochemistry, and development. | Cardaminopsis|Arabidopses|Arabidopsis|arabidopsis | Arabidopsis |
C1262902 | food plant which contains little starch and is rich in protein; used to prepare protein supplements; also furnishes commercially important enzymes and other products. | Soya bean|glycine max|Glycine max|soybean|Glycine max (organism)|soybeans|Soja hispida|Soybean|Chinese bean | Glycine max |
C0019587 | A group of enzymes including those oxidizing primary monoamines, diamines, and histamine. They are copper proteins, and, as their action depends on a carbonyl group, they are sensitive to inhibition by semicarbazide. | Oxidase, Copper Amine|amine oxidase copper|amine oxidase copper containing|Oxidase, Semicarbazide-Sensitive Amine|Copper Amine Oxidase|Histaminase|Oxidase, Copper-Containing Amine|copper containing amine oxidase|Amine oxidase (copper-containing)|histaminase|diamino oxhydrase|diamine oxidase|Amine:oxygen oxidoreductase (deaminating)(copper-containing)|amine oxidase (copper)|Semicarbazide Sensitive Amine Oxidase|Semicarbazide-Sensitive Amine Oxidase|Diamino oxhydrase|Amine Oxidase, Semicarbazide-Sensitive|Amine Oxidase, Copper Containing|Diamine Oxidase|Amine Oxidase, Copper-Containing|Amine Oxidase, Copper|Diamine oxidase|Oxidase, Diamine|Amine oxidase (pyridoxal containing)|Copper-Containing Amine Oxidase|Amine Oxidase (Copper-Containing)|Amine oxidase (copper-containing) (substance) | Amine Oxidase (Copper-Containing) |
C0242726 | The usually underground portions of a plant that serve as support, store food, and through which water and mineral nutrients enter the plant. (From American Heritage Dictionary, 1982; Concise Dictionary of Biology, 1990) | plants root|Plant Roots|Plant roots (substance)|Roots, Plant|root|Root, Plant|Plant Root|Root|Radix|Roots|roots|plant roots|Plant roots | Plant Roots |
C0034170 | A toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. | 1,4-Butanediamine|1,4 Diaminobutane|Putrescine (substance)|Putrescine|1,4 Butanediamine|PUTRESCINE|1,4-Butylenediamine|1,4-Tetramethylenediamine|1,4-Diaminobutane|putrescine|Butane-1,4-Diamine|Tetramethylenediamine | Putrescine |
C0052331 | null | Arginine decarboxylase (substance)|arginine decarboxylase|Arginine decarboxylase | Arginine decarboxylase |
C0036563 | The encapsulated embryos of flowering plants. They are used as is or for animal feed because of the high content of concentrated nutrients like starches, proteins, and fats. Rapeseed, cottonseed, and sunflower seed are also produced for the oils (fats) they yield. | plant seeds|Spermatophyta|Seed (substance)|Plant Zygote|seeds|Plant seeds (substance)|seed plants|Seeds|Seed|Plant Embryos|seed|Plant seeds|Zygote, Plant|Embryo, Plant|Semen|Embryos, Plant|Plant Embryo|Zygotes, Plant|Plant Zygotes|planting seed | Plant seeds |
C0319634 | null | tuber organism|Genus Tuber|Genus Tuber (organism)|tubers|Tuber, NOS|Truffle|truffles|Tuber|tuber | Genus Tuber (fungus) |
C0032433 | Amine compounds that consist of carbon chains or rings containing two or more primary amino groups. | polyamine|Polyamines|polyamines|Polyamine Compound|Polyamine (substance)|Polyamine | Polyamines |
C0037871 | A polyamine formed from putrescine. It is found in almost all tissues in association with nucleic acids. It is found as a cation at all pH values, and is thought to help stabilize some membranes and nucleic acid structures. It is a precursor of spermine. | spermidine|Spermidine|4-Azaoctamethylenediamine|SPERMIDINE|1,5,10-Triazadecane|1,4-Diaminobutane, N-(3-Aminopropyl)-|Spermidine (substance)|1,4-Butanediamine, N-(3-Aminopropyl)-|1,4-Butanediamine, N1-(3-Aminopropyl)-|4-Azaoctane-1,8-Diamine|N-(3-Aminopropyl)-1,4-Butane-Diamine|1,4-Butanediamine, N-(3-aminopropyl)- | spermidine |
C0037874 | A biogenic polyamine formed from spermidine. It is found in a wide variety of organisms and tissues and is an essential growth factor in some bacteria. It is found as a polycation at all pH values. Spermine is associated with nucleic acids, particularly in viruses, and is thought to stabilize the helical structure. | 1,4-Diaminobutane, N,N'-Bis(3-Aminopropyl)-|1,4-Butanediamine, N1,N4-Bis(3-Aminopropyl)-|Spermine|Diaminopropyltetramethylenediamine|1,4-Butanediamine, N,N'-bis(3-aminopropyl)-|Spermina|1,4-Bis(Aminopropyl) Butanediamine|Musculamine|SPERMINE|spermine|1,4-Butanediamine, N,N'-Bis(3-Aminopropyl)-|1,4-Bis(Aminopropyl)Butanediamine|4,9-diazadodecane-1,12-diamine|4,9-Diaza-1,12-Dodecanediamine|Spermine (substance)|N,N'-Bis(3-aminopropyl)-1,4-butanediamine|4,9-Diazadodecamethylenediamine|4,9-diaza-1,12-dodecanediamine|N,N'-Bis(3-Aminopropyl)-1,4-Butanediamine | spermine |
C0001109 | An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2. | Acid phosphatase (substance)|Phosphomonoesterase|Acid Phosphomonoesterase|Acid Monophosphatase|Acid Nucleoside Diphosphate Phosphatase|Acid Phosphomonoester Hydrolase|EC 3.1.3.2|Acid phosphomonoesterase|Acid phosphatase|Acid Phosphohydrolase|Orthophosphoric-monoester phosphohydrolase (acid optimum)|Phosphate-Monoester Phosphohydrolase (Acid Optimum)|Acid Phosphatase|ACP - Acid phosphatase|acid phosphatase|Glycerophosphatase|Orthophosphoric-Monoester Phosphohydrolase (Acid Optimum) | Acid Phosphatase |
C0242437 | Young plants produced at the completion of GERMINATION of SEEDS. | seedling|Sprouts, Plant|Plant Sprouts|Sprouted Seed|Seedlings|Seedling|Seed, Sprouted|Seedling (substance)|Plant Sprout|Seeds, Sprouted|Sprouted Seeds|seedlings|Sprout, Plant | Seedlings |
C1517488 | A set of genes coding for diverse proteins which, by virtue of their high degree of sequence similarity, are believed to have evolved from a single ancestral gene. | null | Gene Family |
C0162740 | null | Cress, Mouse ear|thaliana, A.|Mouse-ear Cress|A. thaliana|Mouse-ear Cresses|mouse-ear cress|Cress, Mouse-ear|Arabidopsis thalianas|thalianas, A.|A. thalianas|Cresses, Mouse-ear|thale-cress|thaliana, Arabidopsis|Arabidopsis thaliana | Arabidopsis thaliana <plant> |
C0330090 | The reproductive organs of plants. | Plant Blooms|flowers|Flowers (substance)|Bloom, Plant|Flowers, NOS|Flower|Blossom|Blooms, Plant|flower|Flos|blossoms|Plant Bloom|blossom|Blossoms|Flowers | Flowers |
C0004728 | null | Rat, Bandicoot|Bandicoot Rat|Bandicoot Rats | Rats, Bandicoot |
C1489791 | null | null | Chorispora bungeana |
C1122962 | A selective tyrosine kinase inhibitor for the EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) that is used for the treatment of locally advanced or metastatic NON-SMALL CELL LUNG CANCER. | 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline|Product containing gefitinib (medicinal product)|gefitinib|Gefitinib (substance)|GEFITINIB|4-quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy]|N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide|4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline|Gefitinib|4-(3chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline|Gefitinib-containing product|N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine|N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine | gefitinib |
C1443775 | Any tyrosine kinase inhibitor that targets the activity of the epidermal growth factor receptor (EGFR) tyrosine kinase. Inhibition of epidermal growth factor receptor tyrosine kinase may inhibit the growth of epidermal-lineage tumor cells, especially those that overexpress epidermal growth factor receptor. | Epidermal Growth Factor Receptor Inhibitor|Substance with epidermal growth factor receptor antagonist mechanism of action|Epidermal Growth-Factor Receptor Inhibitors|EGFR-TK Inhibitor|Product containing epidermal growth factor receptor antagonist (product)|EGFR antagonist|EGFR Inhibitor|Substance with epidermal growth factor receptor antagonist mechanism of action (substance)|EGFR Tyrosine Kinase Inhibitors|EGFR Blocker|EGFR Tyrosine Kinase Inhibitor|Epidermal growth factor receptor antagonist|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Epidermal growth factor receptor antagonist-containing product | Epidermal growth factor receptor inhibitor (product) |
C0086982 | Describes a group of molecules in a cell that work together to control one or more cell functions, such as cell division or cell death. After the first molecule in a pathway receives a signal, it activates another molecule. This process is repeated until the last molecule is activated and the cell function involved is carried out. Abnormal activation of signaling pathways can lead to cancer, and drugs are being developed to block these pathways. This may help block cancer cell growth and kill cancer cells. | signal transduction pathways|signaling pathway|signal transduction pathway|Signal Transduction Pathway|Pathway, Signal Transduction|Signaling Pathway|Signal Transduction Pathways|Pathways, Signal Transduction | Signal Transduction Pathways |
C0007131 | A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. | Non-Small Cell Lung Cancer|Non-small cell lung cancer (disorder)|Non-Small-Cell Lung Carcinomas|Lung Carcinoma, Non-Small-Cell|non-small cell lung cancer|lung cancer non-small cell|carcinoma cell lung non-small|Carcinoma, Non-Small-Cell Lung|Non-Small Cell Carcinoma of the Lung|non small cell lung carcinoma|Carcinoma, Non Small Cell Lung|Non-small cell lung cancer|small non cell lung cancer|Non Small Cell Lung Cancer NOS|Nonsmall Cell Lung Cancer|cancer cell lung non small|nsclc|lung carcinoma non small cell|Carcinoma, Non-Small Cell Lung|Lung Carcinomas, Non-Small-Cell|Lung cancer, non-small cell|cancer cells lung non small|cancer cell lung non-small|Non-Small Cell Carcinoma of Lung|Carcinomas, Non-Small-Cell Lung|nonsmall cell lung cancer|NONSMALL CELL LUNG CANCER|Non-small cell lung cancer, NOS|non small cell lung cancer|NSCLC - Non-small cell lung cancer|Lung Non-Small Cell Carcinoma|Non Small Cell Lung Carcinoma|NSCLC - Non-Small Cell Lung Cancer|Non-Small Cell Cancer of the Lung|non-oat cell lung cancer|Non-small cell lung carcinoma|Non-Small Cell Cancer of Lung|lung cancer, nonsmall cell|lung cancer non small cell|Non-Small Cell Lung Carcinoma|NSCLC|Non-Small-Cell Lung Carcinoma|Nonsmall cell lung cancer|carcinoma cell lung non small | Non-Small Cell Lung Carcinoma |
C0334227 | Cells of, or derived from, a malignant tumor. | cancer cell|malignant cell|Tumour cells, malignant|Malignant Cell|malignant cells|Tumor cells, malignant (morphologic abnormality)|cancers cell|Tumor cells, malignant|Malignant tumour cells|Malignant tumor cells|cells malignant|Cancer Cell|cancer cells | Tumor cells, malignant |
C0387583 | An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS. | Cyclooxygenase 2|Prostaglandin Synthase, COX-2|Prostaglandin H Synthase 2|Cyclooxygenase 2 (substance)|Cyclo Oxygenase II|2 cyclooxygenase|COX 2 Prostaglandin Synthase|COX-2 Prostaglandin Synthase|pghs-2|cyclooxygenase 2|Cyclooxygenase-2|PGHS-2|Synthase, COX-2 Prostaglandin|Prostaglandin-endoperoxide synthase isoform 2|PTGS2|Cyclo-Oxygenase II|h prostaglandin synthase-2|cyclooxygenase-2|Prostaglandin H Synthase-2 | cyclooxygenase 2 |
C0032580 | A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood. | Familial Multiple Polyposus|Familial Polyposis of the Colon|Adenomatous polyposis coli (morphologic abnormality)|Myh-Associated Polyposis|Familial Multiple Polyposes|Polyposus, Familial Multiple|Polyposis Coli, Adenomatous|FPC - Familial polyposis coli|FAP|hereditary adenomatous polyposis coli|Coli, Hereditary Polyposis|adenomatous coli polyposis|polyposis, MYH-associated|COLON, POLYPOSIS, FAMILIAL ADENOMATOUS|Familial Polyposis Syndromes|Adenomatous Polyposes, Familial|adenomatous polyposis coli|Familial polyposis coli|Adenomatous Polyposis, Familial|Familial Multiple Polyposis|Familial Polyposis Syndrome|Adenomatous Polyposis Coli|Polyposis coli|Polyposi, Familial Multiple|Polyposis Coli, Familial|familial polyposis coli|Adenomatous Polyposis of the Colon|Adenomatous Polyposis Coli, Familial|Coli, Adenomatous Polyposis|familial adenomatous polyposis syndrome|Familial Adenomatous Polyposes|MYH-associated polyposis|Familial Adenomatous Polyposis of the Colon|Polyposes, Myh-Associated|Polyposis Syndrome, Familial|Multiple Polyposi, Familial|Hereditary Polyposis Coli|Familial Polyposis Colus|Multiple Polyposus, Familial|Colus, Familial Polyposis|Polyposis, Familial Multiple|familial polyposis|Multiple Polyposes, Familial|polyposis coli|familial adenomatous polyposis|FAP (familial adenomatous polyposis)|Colus, Adenomatous Polyposis|FAP1|familial polyposis syndrome|Polyposis, Myh-Associated|APC - adenomatous polyposis coli|Adenomatous polyposis|Familial Adenomatous Polyposis Syndrome|Hereditary Adenomatous Polyposis Coli|Familial multiple polyposis syndrome|Familial Polyposis Coli|Myh-Associated Polyposes|APC - Adenomatous Polyposis Coli|Polyposis Coli, Hereditary|Colus, Polyposis|APC|Polyposes, Familial Multiple|Colus, Hereditary Polyposis|polyposis familial|APC - Adenomatous polyposis coli|MYH-associated polyposis (disorder)|Polyposis, Familial Adenomatous|FAMILIAL POLYPOSIS OF THE COLON|Familial Multiple Polyposi|Polyposis Colus, Hereditary|ADENOMATOUS POLYPOSIS OF THE COLON|Adenomatous Polyposis Colus|fap|MAP - MYH associated polyposis|Hereditary Polyposis Colus|Familial adenomatous polyposis|Polyposis Colus|Multiple Polyposis, Familial|Familial Multiple Polyposis Syndrome|Familial multiple polyposis syndrome (disorder)|Coli, Familial Polyposis|FAMILIAL ADENOMATOUS POLYPOSIS 1|FPC|Coli, Polyposis|Adenomatous polyposis coli|Familial Adenomatous Polyposis|Myh Associated Polyposis|FAMILIAL POLYPOSIS|familial intestinal polyposis|Polyposis Coli|Familial Adenomatous Polyposis Coli|Polyposes, Familial Adenomatous|Polyposis Colus, Adenomatous|familial adenomatous polyposis coli|FAP - Familial adenomatous polyposis|polyposis, familial adenomatous|Polyposis Colus, Familial|adenomatous polyposis | Adenomatous Polyposis Coli |
C0003211 | Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. | Non-steroidal anti-inflammatory agent, NOS|NSAIDS|Nonsteroidal Anti Inflammatory Agents|Non-Steroidal Anti-Inflammatory Agents|Non Steroidal Anti Inflammatory Agents|Nonsteroidal anti-inflammatory agent|nonsteroidal antiinflammatory agent|NON-STEROIDAL ANTI-INFLAMMATORY AGENTS|Non-steroidal anti-inflammatory drug|NSAID|nonsteroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory agent (product)|nonsteroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory agents|Anti-Inflammatory Agents, Non-Steroidal|NSAID - Non-steroidal anti-inflammatory drug|Nonsteroidal Antiinflammatory Agents|Nonsteroidal Anti-inflammatory Drugs|NSAIDs|Nonsteroidal Antiinflammatory Drug|nonsteroidal anti-inflammatory drugs (NSAIDs)|Non-steroidal anti-inflammatory agent|nsaids|nsaid|Antiinflammatory Agents, Non Steroidal|Non-steroidal anti-inflammatory agent (substance)|Nonsteroidal Anti-Inflammatory Agents|Anti Inflammatory Agents, Nonsteroidal|Antiinflammatory Agents, Nonsteroidal | Anti-Inflammatory Agents, Non-Steroidal |
C1257954 | A nonsteroidal anti-inflammatory drug used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. | Cyclooxygenase 2 Inhibitors|cox 2 inhibitors|coxib|PTGS-2 inhibitor|Cyclooxygenase-2 inhibitor-containing product|Substance with prostaglandin-endoperoxide synthase isoform 2 inhibitor mechanism of action (substance)|Inhibitors, COX2|COX 2 Inhibitors|COX2 Inhibitors|PTGS2 Inhibitor|Product containing prostaglandin-endoperoxide synthase isoform 2 inhibitor (product)|Cyclooxygenase-2 Inhibitors|coxibs|Inhibitors, COX-2|Cyclooxygenase-2 inhibitor|COX-2 Inhibitors|Prostaglandin-endoperoxide synthase isoform 2 inhibitor|cox 2 inhibitor|Inhibitors, Cyclooxygenase-2|COX-2 inhibitor-containing product|PTGS-2 inhibitor-containing product|Prostaglandin-endoperoxide synthase isoform 2 inhibitor-containing product|COX-2 inhibitor|Prostaglandin-Endoperoxide Synthase 2 Inhibitor|Coxibs|cox-2 inhibitor|cyclooxygenase-2 inhibitors|COX2 inhibitor|Cyclooxygenase II Inhibitor|Inhibitors, Cyclooxygenase 2|cyclooxygenase-2 inhibitor|COX-2 Inhibitor | Cyclooxygenase 2 Inhibitors |
C0033551 | An enzyme that converts arachidonic acid into biologically active prostanoids, such as prostaglandins, prostacyclins, and thromboxanes. | COX|Fatty Acid Cyclo-Oxygenase|Synthases, Prostaglandin-Endoperoxide|Prostaglandin H Synthase|Synthase, Prostaglandin H|Synthase, Prostaglandin|prostaglandin synthetase|cyclooxygenases|Prostaglandin Endoperoxide Synthases|prostaglandin G H synthase|cyclooxygenase|Prostaglandin synthase|Endoperoxide Synthetase, Prostaglandin|Cyclo-Oxygenase|Cyclooxygenase, Arachidonic Acid|Fatty Acid Cyclo Oxygenase|prostaglandin synthase|Synthetase, PGH2|Cyclo-Oxygenase (COX)|Cyclo-Oxygenase, Prostaglandin|Prostaglandin Cyclo-Oxygenase|Prostaglandin-Endoperoxide Synthase|Prostaglandin-endoperoxide synthase|Prostaglandin Cyclo Oxygenase|Prostaglandin synthase (substance)|Prostaglandin G-H Synthase|Prostaglandin Synthetase|Cyclase, Hydroperoxide|Cyclo-Oxygenase, Fatty Acid|Hydroperoxide Cyclase|G-H Synthase, Prostaglandin|Arachidonic Acid Cyclooxygenase|Prostaglandin G/H synthase|Synthase, Prostaglandin-Endoperoxide|Cyclooxygenase, Prostaglandin|Prostaglandin synthetase|Prostaglandin G H Synthase|Prostaglandin Cyclooxygenase|PGH Synthase|Synthetase, Prostaglandin H2|(5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase|Synthetase, Prostaglandin|Prostaglandin-Endoperoxide Synthases|Prostaglandin H2 Synthetase|Prostaglandin Endoperoxide Synthetase|cyclo-oxygenase|Synthetase, Prostaglandin Endoperoxide|Cyclo Oxygenase|Synthase, PGH|Cyclooxygenases|PGH2 Synthetase|cox|cyclo oxygenase|Synthase, Prostaglandin G-H|Prostaglandin Synthase|Cyclooxygenase|prostaglandin endoperoxide synthase | Prostaglandin-Endoperoxide Synthase |
C0006949 | A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. | 5-Carbamoyl-5H-dibenz(b,f)azepine|5-Carbamyl-5H-dibenzo(b,f)azepine|Carbamazepen|CBZ|Carbamazépine|CARBAMAZEPINE|Carbamazepina|Carbamazepine (substance)|5H-Dibenz(b,f)azepine-5-carboxamide|Carbamazepinum|carBAMazepine|5-carbamoyl-5H-dibenz[b,f]azepine|5-Carbamoyl-5H-dibenzo(b,f)azepine|carbamazepine|Carbamazepine|Carbamazepine-containing product|Product containing carbamazepine (medicinal product)|carbamazepines|Carbamazepin | carbamazepine |
C0596632 | The migrating motile tip of a growing neuron projection, where actin accumulates, and the actin cytoskeleton is the most dynamic. [GOC:aruk, GOC:bc, ISBN:0815316194, PMID:10082468] | Growth Cone|growth cone | Growth Cones |
C0060926 | A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME. | Gabapentin-containing product|Gabapentina|Gabapentinum|1-(Aminomethyl)cyclohexaneacetic acid|Gabapentine|gabapentin|GABAPENTIN|1-(Aminomethyl)cyclohexaneacetic Acid|Convalis|Product containing gabapentin (medicinal product)|1-(aminomethyl)cyclohexaneacetic Acid|Gabapentino|Gabapentin (substance)|Gabapentin | gabapentin |
C0021557 | An enzyme that catalyzes the formation of myo-inositol-1-phosphate from glucose-6-phosphate in the presence of NAD. EC 5.5.1.4. | Cycloaldolase|Synthase, Myo-Inositol-1-Phosphate|myo-Inositol-1-phosphate synthase (substance)|Inositol Cyclase|Myo-Inositol-1-Phosphate Synthase|Inositol 1 Phosphate Synthase|myo-Inositol-1-phosphate synthase|1L-myo-Inositol-1-phosphate lyase (isomerizing)|Synthase, Inositol-1-Phosphate|Myo Inositol 1 Phosphate Synthase|Cyclase, Inositol|Inositol-1-Phosphate Synthase | myo-Inositol-1-Phosphate Synthase |
C0596902 | Membrane proteins whose primary function is to facilitate the transport of molecules across a biological membrane. Included in this broad category are proteins involved in active transport (BIOLOGICAL TRANSPORT, ACTIVE), facilitated transport and ION CHANNELS. | membrane transport protein|Transport Proteins, Membrane|transporter|transporters|membrane transport proteins|Membrane Transport Proteins|membrane transporter|Membrane Transporters|Transporters, Membrane | Membrane Transport Proteins |
C1158770 | The control of gene expression at the level of RNA transcription. | transcriptional control|Transcriptional Control|Transcription Regulation | Transcriptional Regulation |
C0443640 | null | specific antibody|antibodies specific|Specific antibody (substance) | Specific antibody |
C0443640 | null | specific antibody|antibodies specific|Specific antibody (substance) | Specific antibody |
C0020964 | Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. | Immunity, NOS|immune status|Immune state, NOS|Immune status (observable entity)|immunity|Immune status|Immune status, NOS|biological immunity|Immunity | Immunity |
C0231530 | The occurrence of a single contraction or a series of contractions of a muscle. | Twitching|muscle twitch|jerk|muscle twitching|MUSCLE TWITCH|TWITCHING|jerked|Muscle twitch (finding)|Twitch|twitch|jerks|twitched|twitches|twitching|jerking|Muscle twitch | Muscle twitch |
C0507621 | null | Lumbar intervertebral symphysis|Entire joint of lumbar vertebral bodies|Entire joint between lumbar vertebral bodies (body structure)|Joint of lumbar vertebral body|Entire lumbar intervertebral joint | Entire joint between lumbar vertebral bodies |
C0037004 | Part of the body in humans and primates where the arms connect to the trunk. The shoulder has five joints; ACROMIOCLAVICULAR joint, CORACOCLAVICULAR joint, GLENOHUMERAL joint, scapulathoracic joint, and STERNOCLAVICULAR joint. | Shoulders|shoulder|Shoulder region|Shoulder|shoulders|SHOULDER|shoulder anatomy|Shoulder region structure (body structure)|shouldering|Sholder Joint|Shoulder, NOS|anatomy shoulder|anatomies shoulder|Shoulder region structure | Shoulder |
C1265658 | null | dislocation anterior|Anterior dislocation|anterior dislocation|Anterior dislocation (morphologic abnormality) | Anterior dislocation |
C1280541 | null | Entire nerve|Entire nerve (body structure) | Entire nerve |
C0014547 | Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317) | Partial Seizure Disorders|Localisation-related epilepsy|Focal Seizure Disorders|focal seizure disorder|Focal Seizure Disorder|Partial Epilepsy|local epilepsy|Seizure Disorder, Partial|Localization-related epilepsy (disorder)|Focal Epilepsies|Epilepsy, Partial|Localization-related epilepsy, NOS|Seizure Disorders, Focal|Epilepsies, Partial|Localization-Related Epilepsies|partial epilepsy|Localization-Related Epilepsy|Focal Epilepsy|Disorders, Partial Seizure|Epilepsies, Localization-Related|Focal epilepsy|Epilepsy, focal NOS|Local epilepsy|Focal epilepsy, NOS|Epilepsy, Focal|Epilepsy, focal|Partial Seizure Disorder|Partial epilepsy|Epilepsy, partial NOS|Localization-related epilepsy|LOCALIZATION-RELATED EPILEPSIES|Seizure Disorder, Focal|Epilepsies, Focal|epilepsy focal|Epilepsy, Localization-Related|Disorders, Focal Seizure|focal epilepsy|Seizure Disorders, Partial|Partial Epilepsies|partial seizure disorder | Epilepsies, Partial |
C0036572 | Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or "seizure disorder." | Convulsion, NOS|sz|Seizure|fits|seizure|Convulsion|seizures|Seizure NOS|Fit - convulsion|Fits NOS|CONVULSION|Seizure (finding)|Seizure, NOS|CONVULSIONS|Fitting|SEIZURE|convulsions nos|Fit, NOS|fitted|seizure d|fit's|Convulsions|convulsion|Seizures|convulsions|fit|CONVULSION (NOS)|Fit | Seizures |
C0085639 | A sudden movement downward, usually resulting in injury. | falling|FALL|down falls|fall|Fall (event)|fall injury|FALLING DOWN|Fall NOS|FALLS|Fall, NOS|Fall|falls|falling down|fall down|Unspecified fall|Falls (finding)|Falls|FALLING | Falls |
C1293903 | null | vagal stimulation|Vagal stimulation physiologic challenge (procedure)|Vagal stimulation physiologic challenge | Vagal stimulation |
C0442045 | Of, or relating to, or affecting the internal organs. | Visceral|Visceral (qualifier value)|visceral | Visceral |
C0001527 | Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white. | Unilocular adipose tissue|Tissue, Adipose|fatty tissues|Adipocytus unigutturalis|Human Adipose Tissue|Tissue, Fatty|Fatty tissue|Fat Tissue|Fatty Tissue|Yellow fat (body structure)|adipose tissue|ADIPOSE TISSUE|Adipose Tissue|Body Fat|yellow adipose tissue|fat tissue|Textus adiposus albus|fatty tissue|fat tissues|yellow fat|Adipose tissue (body structure)|Yellow fat|fat yellow|Adipose tissues|adipose fat body|adipose tissues|Adipose tissue | Adipose tissue |
C0011777 | An anti-inflammatory 9-fluoro-glucocorticoid. | dexamethasone (DMX)|Dexamethasone preparation|Fluoro-9alpha Methyl-16alpha Prednisolone|Dexamethasone (substance)|9alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione|16α-Methyl-9α-fluoro-1-dehydrocortisol|9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione|9Alpha-fluoro-16alpha-methylprednisolone|Dexaméthasone|Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-|9alpha-Fluoro-16alpha- methylprednisolone|Dexametasona|DM|16alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione|Dexamethasonum|9alpha-Fluoro-16alpha-methylprednisolone|16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione|Dexamethasone|(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione|Hexadecadrol|9α-Fluoro-16α-methylprednisolone|1-dehydro-16alpha-methyl-9alpha-fluorohydrocortisone|DEXAMETHASONE|Dexamethasone-containing product|Product containing dexamethasone (medicinal product)|DXM|16Alpha-methyl-9alpha-fluoroprednisolone|dexamethasone|16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone|16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol|16alpha-methyl-9alpha-fluoroprednisolone|disaimisong|(11beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione|Desamethasone|16alpha-methyl-9alpha-fluoro-delta1-hydrocortisone|Methylfluorprednisolone|1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone|1-Dehydro-16α-methyl-9α-fluorohydrocortisone | dexamethasone |
C0021246 | A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. | indomethacin|{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid|Indometacin-containing product|Indometacin|INDOMETHACIN|Indometacinum|Indometacine|Indomethacin-containing product|1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid|INDO|Indometacina|1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid|Indomethacin|Indometacin (substance)|Product containing indometacin (medicinal product)|indometacin|1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- | indomethacin |
C0028351 | Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. | l-Norepinephrine|noradrenalin|(R)-noradrenaline|(-)-noradrenaline|Noradrenalin|1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-|Levarterenol|Norepinefrina|Arterenol|Norepinephrinum|Norepinephrine-containing product|Product containing norepinephrine (medicinal product)|NOREPINEPHRINE|(R)-(-)-norepinephrine|Noradrenaline-containing product|(-)-norepinephrine|Norepinephrine preparation|(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol|(-)-alpha-(aminomethyl)-3,4-dihydroxybenzyl Alcohol|l-3,4-Dihydroxyphenylethanolamine|(R)-norepinephrine|(-)-arterenol|levarterenol|Noradrenaline|Norepinephrine|Nor-adrenaline|Norépinéphrine|Levonorepinephrine|Norepinephrine (substance)|L-Norepinephrine|(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol|l-Noradrenaline|l-Arterenol|L-noradrenaline|noradrenaline|4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol|Noradrenaline preparation|norepinephrine|norepinephrines | norepinephrine |
C0002520 | Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. | amino acid|Amino acids NOS|Amino acids|AA - Amino acid|aa|aminoacids|amino acids|Amino Acids|AMINO ACIDS|Amino Acid|AMINO ACID PREPARATION|Amino acid, NOS|Acids, Amino|Product containing amino acid (product)|Amino acid-containing product|Amino acid|Amino acid (substance)|aminoacid | Amino Acids |
C1260899 | A rare congenital hypoplastic anemia that usually presents early in infancy. The disease is characterized by a moderate to severe macrocytic anemia, occasional neutropenia or thrombocytosis, a normocellular bone marrow with erythroid hypoplasia, and an increased risk of developing leukemia. (Curr Opin Hematol 2000 Mar;7(2):85-94) | Diamond Anemia, Blackfan|Congenital Erythroid Hypoplastic Anemia|Congenital Pure Red Cell Anemia|Anemia, Diamond Blackfan Type|Diamond-Blackfan anaemia|Congenital pure red cell anemia|inherited erythroblastopenia|blackfan diamond anaemia|Blackfan Diamond Anemia|blackfan diamond syndrome|Erythroblastopenia, Inherited|Inherited Erythroblastopenia|Congenital pure red cell anaemia|Anemias, Hypoplastic Congenital|Chronic constitutional pure red cell anemia|Chronic Congenital Agenerative Anemia|Hypoplastic Congenital Anemia|Red Cell Aplasia, Pure, Hereditary|BLACKFAN-DIAMOND SYNDROME|Chronic constitutional pure red cell anaemia|Disease, Blackfan-Diamond|diamond blackfan anaemia|anemia blackfan diamond|Blackfan-Diamond anemia|Congenital Anemias, Hypoplastic|Blackfan-Diamond syndrome|Imperfecta, Erythrogenesis|Blackfan Diamond Syndrome|Anemia, Hypoplastic Congenital|Pure Hereditary Red Cell Aplasia|Erythrogenesis Imperfecta|diamond-blackfan syndrome|diamond-blackfan anemia|Congenital hypoplastic anemia|Erythrogenesis Imperfectas|congenital pure red cell aplasia|blackfan-diamond syndrome|DBA|CONGENITAL RED CELL APLASIA|Anemia, Blackfan Diamond|congenital hypoplastic anemia|diamond-blackfan anaemia|blackfan diamond anemia|Blackfan Diamond Disease|Diamond-Blackfan Type Anemia|Hypoplastic Congenital Anemias|Blackfan-Diamond Disease|Imperfectas, Erythrogenesis|Congenital hypoplastic anemia (disorder)|Diamond Blackfan Anemia|familial hypoplastic anaemia|Blackfan-Diamond Syndrome|Congenital Hypoplastic Anemia of Blackfan and Diamond|Diamond-Blackfan Anemia|Diamond-Blackfan syndrome|Anemia, Diamond Blackfan|Erythrogenesis imperfecta|Congenital Pure Red Cell Aplasia|Anemia, Diamond-Blackfan Type|Congenital red cell aplasia|Chronic constitutional pure red cell aplasia|Congenital Anemia, Hypoplastic|Erythroblastopenias, Inherited|Anemia, Congenital Hypoplastic, Of Blackfan And Diamond|Anemia, Diamond-Blackfan|diamond blackfan anemia|diamond blackfan syndrome|erythrogenesis imperfecta|Diamond-Blackfan anemia|Congenital pure red cell aplasia|Inherited Erythroblastopenias | Anemia, Diamond-Blackfan |
C0235983 | null | ANEMIA NORMOCHROMIC|NORMOCHROMIC ANEMIA|Anemia, normochromic|normochromic anemia|Normochromic anemia|ANAEMIA NORMOCHROMIC|normochromic anaemia | Normochromic anemia |
C0522578 | null | null | Normocellular |
C0858867 | Abnormally low level of immature red blood cells in the blood. | Reticulocytopenia|Reticulocytopenia (finding)|Reticulocyte count below reference range | Reticulocytopenia |
C0073320 | 40S ribosomal protein S19 (145 aa, ~16 kDa) is encoded by the human RPS19 gene. This protein is involved in the maturation of the 40S ribosomal subunit and in pre-rRNA processing. | 40S Ribosomal Protein S19|ribosomal protein S19|RPS19|S19 ribosomal protein|Small Ribosomal Subunit Protein eS19|Ribosomal Protein S19 | ribosomal protein S19 |
C1513776 | To change the genetic material of a cell. The changes (mutations) can be harmful, beneficial, or have no effect. | mutate | Mutate |
C0002520 | Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. | amino acid|Amino acids NOS|Amino acids|AA - Amino acid|aa|aminoacids|amino acids|Amino Acids|AMINO ACIDS|Amino Acid|AMINO ACID PREPARATION|Amino acid, NOS|Acids, Amino|Product containing amino acid (product)|Amino acid-containing product|Amino acid|Amino acid (substance)|aminoacid | Amino Acids |
C1262483 | null | Hereditary stomatocytosis (disorder)|Stomatocytosis, congenital|Hereditary hydrocytosis|Hereditary stomatocytosis | Hereditary stomatocytosis |
C1335068 | Neurogenic locus notch homolog protein 1 (2555 aa, ~273 kDa) is encoded by the human NOTCH1 gene. This protein is involved in both cell-cell signaling and cell-fate determination. | notch-1 protein, human|Neurogenic Locus Notch Homolog Protein 1|TAN-1|TAN1|NOTCH1 protein, human|Notch1 Preproprotein|Notch homolog 1, translocation-associated (Drosophila) protein, human|Notch Homolog 1|Translocation-Associated Notch Protein TAN-1|hN1|TAN1 protein, human|TAN-1 protein, human|NOTCH1 | NOTCH1 protein, human |
C0027923 | A species of ascomycetous fungi of the family Sordariaceae, order SORDARIALES, much used in biochemical, genetic, and physiologic studies. | crassas, Neurospora|Neurospora crassa|Neurospora crassas | Neurospora crassa |
C0051609 | Amino acid transporters found in yeasts, plants and lower organisms. However, the distinction between the terms permease and transporter has not been consistently maintained in the literature. | Permeases, Amino Acid|Amino Acid Permease|Permease, Amino Acid|Amino Acid Permeases | Amino Acid Permease |
C0872306 | Proteins found in any species of yeast. | Yeast Protein|yeast protein | Yeast Proteins |
C1326356 | The directed movement of amino acids into a cell or organelle. [GOC:jl] | amino acid uptake | amino acid import |
C0997303 | null | Phytophthora parasitica|Phytophthora parasiticas|parasitica, Phytophthora | Phytophthora parasitica |
C0319683 | null | Oyster Mushroom|Oyster mushroom|shimeji|Mushroom, Oyster|Mushrooms, Oyster|oyster mushrooms|Pleurotus ostreatus|Pleurotus ostreatus (organism)|Oyster Mushrooms | Pleurotus ostreatus |
C1550272 | null | Lamella | Lamella |
C0007623 | The outermost layer of a cell in most PLANTS; BACTERIA; FUNGI; and ALGAE. The cell wall is usually a rigid structure that lies external to the CELL MEMBRANE, and provides a protective barrier against physical or chemical agents. | Wall, Cell|cell walls|cell wall|Cell Walls|Walls, Cell | Cell Wall |
C0017696 | Polysaccharides composed of repeating glucose units. They can consist of branched or unbranched chains in any linkages. | glucans|Polyglucoses|Polymer, Glucose|Glucose Polymer|Glucans|polyglucose|glucan|glucose polymers | Glucans |
C0032594 | A large carbohydrate molecule. It contains many small sugar molecules that are joined chemically. | Glycans|polysaccharides|Polysaccharide|Polysaccharide (substance)|polysaccharide|glycans|Polysaccharides|glycan|Polysaccharide, NOS | Polysaccharides |
C0025196 | Insoluble polymers of TYROSINE derivatives found in and causing darkness in skin (SKIN PIGMENTATION), hair, and feathers providing protection against SUNBURN induced by SUNLIGHT. CAROTENES contribute yellow and red coloration. | melanins|Melanins|Melanin|Melanin (substance)|melanin | Melanins |
C0004038 | A species of imperfect fungi from which the antibiotic nidulin is obtained. Its teleomorph is Emericella nidulans. | nidulan, Aspergillus|Aspergillus nidulans (organism)|Aspergillus nidulan|Aspergillus nidulans|Aspergillus nidulellus | Aspergillus nidulans |
C0017362 | Genes which regulate or circumscribe the activity of other genes; specifically, genes which code for PROTEINS or RNAs which have GENE EXPRESSION REGULATION functions. | Regulator gene|Regulator Gene|Genes, Regulatory|regulator gene|trans acting element|Gene, Regulatory|genes regulatory|Regulator Genes|regulatory gene|Regulatory Gene|Gene, Regulator|Regulatory Genes|Regulator gene (substance)|gene regulatory | Genes, Regulator |
C0683154 | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease. [GOC:jl] | response to drug|drugs response|drug response|drug responses | drug response |
C0041755 | Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals. | drug adverse effect|Drug-Related Side Effects and Adverse Reactions|Adverse drug effect|Adverse Drug Reaction|drug adverse reactions|Drug Reactions, Adverse|Adverse Drug Experience|Adverse drug response|adverse drug events|Drug Reactions|Adverse drug effect, NOS|Drug Side Effects|Adverse drug reaction|Adverse reaction to drug|drug reaction|medication reactions|adverse drug reaction|Adverse Drug Reactions|drug side effect|Drug Related Side Effects and Adverse Reactions|Adverse Drug Events|adverse drug experience|Toxic drug response|DRUG REACTION|drug adverse reaction|Adverse reaction caused by drug (disorder)|medication reaction|drug side effects|adverse drug reactions|Drug, adverse effect|Adverse drug reaction, NOS|Reactions, Adverse Drug|medications side effect|Adverse reaction caused by drug|Drug Reaction, Adverse|side effect (drug)|Side Effects of Drugs|Drug reaction, NOS|Adverse reaction to medication|medications reaction|reaction medication|adverse drug event|Drug Event, Adverse|Drug Side Effect|Effects, Drug Side|medications reactions|Side Effect, Drug|adverse drug reaction (ADR)|Drug reaction|ADR|medication adverse effects|ADR - Adverse drug reaction|adverse drug effects|Side Effects, Drug|adverse drug effect|medication side-effect|medication side effect|Drug Events, Adverse|medication side effects|Drug reaction (qualifier value)|Adverse Drug Event | Adverse reaction to drug |
C0014544 | A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) | disorders seizures|CLINICAL EPILEPSY DIAGNOSES|Epilepsy|seizure epileptic|Epilepsy, NOS|Epilepsies|Seizure disorder|seizure disorders|Seizure syndrome|disorder epilepsy|epilepsy types|Epileptic disorder, NOS|Epilepsy (disorder)|epileptic fits|Epilepsy, unspecified|SEIZURE DISORDER|syndrome seizure|seizure disorder|epileptic fit|Seizure Syndromes|EPILEPSY|seizures syndrome|epilepsy|Seizure Disorder|epileptic|seizure syndrome|convulsion epileptic|Epileptic seizures, NOS|disorder seizures|Seizure Disorders|epilepsies|Epileptic fits, NOS|epilepsis|Epileptic attack, NOS|Epileptic|Epileptic disorder|disorders seizure|disorders epileptic|attacks epileptic|epileptic attack|epilepsia|Seizure disorder NOS|epileptics|Epileptic convulsions, NOS|epileptic seizures|epileptic seizure|Seizure disorder (disorder)|disorder seizure|CLINICAL EPILEPTIC SYNDROMES AND SEIZURES|EP - Epilepsy|seizures syndromes | Epilepsy |
Subsets and Splits